The Qt Company Ltd (“The Qt Company”), a wholly owned subsidiary of Qt Group Plc, has announced a public tender offer to the shareholders of I.A.R. Systems Group AB (publ) (“IAR”) to tender all class B shares in IAR to The Qt Company at a price of SEK 180 in cash per share

IAR provides software and services for embedded development used by companies worldwide for creation of secure products. Headquartered in Uppsala, Sweden, IAR has a global presence of sales and support offices worldwide. The shares in IAR are traded on Nasdaq Stockholm, Mid Cap. The offer values IAR at approximately SEK 2,293 million.


Vinge’s team mainly consists of Rikard Lindahl, Erik Sjöman, Joel Magnusson, Benjamin Vafaeian, Louise Nässén and Vilma Henricsson (Capital Markets and Public M&A), Jonas Johansson (M&A), Arvid Weimers, Josefine Lanker, Nour Makie and Katja Häglund (Banking and Finance), Johanna Fjellström and Alice Göransson (Labor Law), Rebecka Målquist and Melinda Oldenburg (IP), Eva Fredrikson, Martin Boström, Siri Blomberg and Filippa Eriksson (Commercial agreements, IT and GDPR), Fredrik Hellström and Lovisa Arpi (FDI), Gulestan Ali (Compliance) and Diana Kanold (VDR).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026